Relapse after allogeneic hematopoietic cell transplantation (HCT) is the leading cause of death in patients with acute myeloid leukemia (AML) entering HCT with poor-risk features [1] [2] [3] . When HCT does produce prolonged relapse-free survival, it commonly reflects graft-versus-leukemia effects mediated by donor T cells reactive with antigens on leukemic cells 4 . As graft T cells have not been selected for leukemia specificity and frequently recognize proteins expressed by many normal host tissues, graft-versus-leukemia effects are often accompanied by morbidity and mortality from graft-versushost disease 5 . Thus, AML relapse risk might be more effectively reduced with T cells expressing receptors (TCRs) that target selected AML antigens 6 . We therefore isolated a high-affinity Wilms' Tumor Antigen 1-specific TCR (TCR C4 ) from HLA-A2 + normal donor repertoires, inserted TCR C4 into Epstein-Bar virus-specific donor CD8 + T cells (T TCR-C4 ) to minimize graftversus-host disease risk and enhance transferred T cell survival 7, 8 , and infused these cells prophylactically post-HCT into 12 patients (NCT01640301). Relapse-free survival was 100% at a median of 44 months following infusion, while a concurrent comparative group of 88 patients with similar risk AML had 54% relapse-free survival (P = 0.002). T TCR-C4 maintained TCR C4 expression, persisted long-term and were polyfunctional. This strategy appears promising for preventing AML recurrence in individuals at increased risk of post-HCT relapse.
To identify targetable antigens in AML, we evaluated leukemic stem cells for differentially expressed genes that promote the leukemic phenotype 9 . Wilms' Tumor Antigen 1 (WT1) is a nonpolymorphic intracellular protein that promotes proliferation and oncogenicity in AML, and is over-expressed 10-1,000 times in AML, including leukemic stem cells, compared with normal CD34 + cells 9, 10 . Although essential during embryogenesis, physiologic WT1 expression is limited to low levels in a few adult tissues, predominantly kidney podocytes, mesothelial lining cells and hematopoietic
CD34
+ stem cells 11 . Based on similar over-expression in other malignancies, WT1 was identified as a high-priority antigen target by the US National Cancer Institute 12 .
The binding affinity of a TCR for its target antigen largely determines the avidity of the T cell carrying that TCR; that is, its ability to mediate anti-tumor effector functions 13 . In a previous clinical study, we demonstrated direct anti-leukemia activity of WT1-specific CD8 + T cell clones transferred post-HCT
14
. Although the highest avidity T cell clones were selected from each patient's HLA-matched donor, most endogenous WT1-specific T cells were of low avidity. To increase potency in the anti-WT1 TCR study described here, we screened many donors to identify a high-affinity, HLA-A*0201 + (HLA-A2)-restricted WT1-specific TCR (denoted TCR C4 ) that could impart consistently high avidity for WT1-expressing targets 15 . Challenges for a TCR targeting an overexpressed self-antigen in the post-HCT setting include potential on-target, off-tissue toxicity mediated by the introduced TCR, and alloreactivity mediated by endogenous donor TCRs, as previously observed with donor lymphocyte infusions 4 . To minimize the first risk, TCR C4 was purposefully isolated from the peripheral repertoire of a healthy HLA-A2 + donor, guaranteeing that the TCR had passed thymic negative selection and did not mediate a peripheral autoimmune process 16 . To decrease the likelihood of an endogenous TCR inducing graft-versus-host disease (GVHD) 15 , we used donor Epstein-Barr virus (EBV)-specific cells, which can be readily isolated from most HCT donors 17 . Post-transfer T cell persistence is necessary to maintain immune responses that can achieve eradication and/or prevent late leukemia recurrences 18 . In our previous trial, most selected T cell clones had been extensively expanded and were terminally differentiated, with limited replicative capacity, and persisted for less than 14 d in vivo 14 . By using TCR-transduced donor cells, limited expansion is needed to achieve necessary cell doses, and EBV-specific substrate cells are naturally enriched for central memory T cells (TCM)
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To assess EBV-specific T TCR-C4 anti-tumor/anti-viral activity ex vivo, the avidity of T TCR-C4 was comparable to the highest-avidity endogenous WT1-specific CD8 + T cell clones infused in our previous study (Fig. 1a) 
14
. T TCR-C4 also efficiently killed fresh leukemia cells (Fig. 1b) . TCR C4 expression was maintained in transduced cells after repeated cycles of in vitro expansion, whereas the endogenous EBV-specific TCR was selectively down-regulated in a fraction of T TCR-C4 (Fig. 1c) . This probably resulted from enhanced expression of the codon-optimized TCR C4 , regulated by the strong murine stem cell virus (MSCV) promoter, out-competing endogenous TCRs for limiting CD3 complexes required for membrane expression 20 (Fig. 1d) . T TCR-C4 produced significantly more interferon-γ (IFN-γ), tumor-necrosis factor-α (TNF-α) and interleukin-2 (IL-2) in response to stimulation with WT1 peptide, compared with EBV peptide (Fig. 1e and Supplementary Fig. 1 ). After in vitro expansion, T TCR-C4 expressed molecules found in T CM and associated with survival and self-renewal, including CD28 ref. 21 ), CD27 (ref.
22
) and CD127 (ref. 23 ), but <20% expressed the T CM -associated lymph node-homing molecules CD62L and CCR7 (ref.
24
). T TCR-C4 also expressed activation/inhibitory receptors, including PD1, CD160 and LAG3 ( Fig. 1f and Supplementary Fig. 2 ) 25 . By contrast, EBVspecific T cells that were isolated from donor leukaphereses by tetramer binding (tet + ) to serve as TCR C4 -transduction substrates expressed CD62L and CCR7 (median 58.3% and 13.7%); these cells expressed few activation/inhibitory receptors, except for PD1, probably reflecting a stably transmitted T CM phenotype acquired during persistent viral infection, previously reported not to interfere with function ( Fig. 1g) 
26
.
To determine if T TCR-C4 could prevent AML recurrence in patients at increased risk of post-HCT relapse, 12 poor-risk patients (Table  1 and Supplementary Fig. 3 ), with no evaluable disease (NED) at ~28 d post-HCT and before subsequent infusions [27] [28] [29] , received 21 infusions (Extended Data Figs. 1 and 2). All received at least 1 infusion of 10 10 m −2 EBV-specific substrate T TCR-C4 (maximum target dose); 7 patients with limited in vivo T cell persistence received a second infusion of 10 10 m −2 21-797 d after the first infusion (see Methods). Three and 2 patients, respectively, did not receive a second infusion due to maintaining T TCR-C4 frequencies above the safety threshold (3% of total CD8 + T cells) or due to personal preference/ convenience. AML status was assessed at least once post-T TCR-C4 infusion(s), and then as clinically indicated (Fig. 2a) . With a median follow-up of 44 months (range 21-57 months) following the first T TCR-C4 infusion, all 12 patients had NED at all post-T TCR-C4 bone marrow assessments and remained alive with no additional AMLspecific treatment (Fig. 2a-c) .
To provide clinical context for patient outcomes, we identified a comparator group of 88 patients with AML with NED at day ~28 post-HCT marrow evaluation and who concurrently received HCT at our institution. Some of these patients also had a negative marrow evaluation at ~day 80. These patients had similar demographics, risk assessments and HCT characteristics as in our study cohort (Extended Data Fig. 3 ). Among the 88 comparative-group patients, there were 35 deaths (39%) and 25 relapses (28%), resulting in a total of 40 failures (relapse or death, 45%) (Fig. 2d,e) . The 3-yr estimates of relapse-free survival (RFS), overall survival, relapse and non-relapse mortality following NED assessments among comparator patients were 54%, 60%, 28% and 18%, respectively, as compared with 100%, 100%, 0% and 0% for T TCR-C4 -treated patients. Using statistical methods described in the Methods, the formal comparison yields P = 0.002 for both overall survival and RFS, and P = 0.01 for relapse. Hazard ratios were zero for the T TCR-C4 versus comparative group, as there were no relapses or deaths in the T TCR-C4 group.
We sought to determine whether non-T TCR-C4 factors might explain the encouraging results observed in T TCR-C4 -treated patients. The risk of chronic GVHD, which can be associated with a lower relapse rate due to graft-versus-leukemia (GVL) effect 30 , was not significantly different between T TCR-C4 -treated and comparative group patients (55% and 61%, respectively; hazard ratio, 0.78; 95% confidence interval (95% CI), 0.33-1.84; P = 0.57). All T TCR-C4 -treated patients were necessarily HLA-A2 + , but the subset of HLA-A2 + patients (44%) in the comparator group had a comparable overall survival (hazard ratio, 0.72; 95% CI, 0.37-1.44) and RFS (hazard ratio, 0.91; 95% CI, 0.49-1.71) to HLA-A2 − patients, suggesting that the HLA-A2 allele did not drive improved outcomes. Post-HCT recovery of hematocrit, platelet, neutrophil and lymphocyte counts was similar for T TCR-C4 -treated patients after their infusion, and for comparative group patients who remained alive after day 80 post-HCT (Extended Data Fig. 4) .
We then assessed if T TCR-C4 is associated with toxicity to normal tissues. Infusions were well tolerated (Extended Data Fig. 5 ). Nine and 9 patients exhibited grade 1-2 GVHD before and after T TCR-C4 infusions, respectively (Extended Data Fig. 6 ). Only 1 T TCR-C4 -treated patient (patient 12) developed grade 3 acute GVHD with onset 97 d after the T TCR-C4 infusion. Biopsies obtained from patients 10 and 11 (chronic GVHD) and patient 12 (late acute GVHD) demonstrated lower frequencies of T TCR-C4 in affected tissue, compared with blood, suggesting the absence of preferential localization. GVHD also did not correlate with T TCR-C4 infusions, as onset occurred well after infusions (range 65-295 d, median 123 d). Thus, the signs of GVHD could not be associated with T TCR-C4 , either temporally or by localization of transferred cells.
We assessed if EBV-specific T TCR-C4 persisted post-infusion. Only rare, pre-existing WT1-specific tet + T cells were detected in peripheral blood mononuclear cells (PBMCs; range 0.01% (limit of detection) to 0.026%) (Fig. 2f, day 0) . Nine of 12 patients achieved frequencies >3% of CD8 + T cells at day 28 after the first infusion, with 4 of 12 (patients 10, 11, 12 and 18) maintaining this level for >365 d; these frequencies were associated with high absolute T TCR-C4 counts (Extended Data Fig. 7a ). These 4 patients demonstrated T TCR-C4 frequencies >10% (range 11-51% tet + CD8 + T cells) at 365 d postinfusion. Patients 10 and 12, with the longest follow-up, maintained frequencies of 29.2% and 49.7% at 912 and 1,014 d, respectively. . a, Mean effective concentrations of peptide required to achieve 50% lysis (EC 50 ) of WT1 peptide-pulsed TAP-deficient HLA-A2 + B cell lymphoblastoid cells (T2 B-LCL) by Jurkat-Nur77 T cells transduced with TCRs isolated from infused clonal cell products (from our previous study) and T TCR-C4 . b, Lysis of three independent HLA-A2 + (red shades) primary leukemias versus an HLA-A2 − (black) primary leukemia by donor T TCR-C4 at decreasing effector-to-target (E/T) ratios. For each independent leukemia, the median (dots) and standard error (bars) of triplicate values (n = 3) are shown. c, Specific downregulation of the endogenous EBV-specific TCR after TCR C4 transduction during the product generation process shown for a representative patient (patient 10). These experiments were repeated >3 times with similar results. Binding of TCR C4 -transduced (top panels) and non-transduced EBV-specific cells (lower panels) to WT1 (y axis) and EBV (x axis) tetramers before (left panels) or immediately after day 7 sorting (second to left panels) and after 2 rounds of expansion with anti-CD3/CD28 stimulus (rightmost panels). d, Percentage of WT1-tet + T TCR-C4 that also bound EBV tetramer, for infused products (n = 12). e, Percentage of WT1 tet + T TCR-C4 within the infusion products (n = 12) that produced IFN-γ, TNF-α or IL-2 in response to WT1 126-134 (red, n = 12 individual values) and EBV BMLF1 280-288 (green, n = 11 individual values) peptides. f,g, Expression of CD27, CD28, CD127, CD62L, CCR7, PD-1 (n = 12 individual values), TIM3 (n = 11) and LAG3 (n = 12) in infused T TCR-C4 products (n = 12) (f) and EBV-specific T cells (g) in donor leukapheresis (n = 8). For all figures: box and whisker plots include range (whiskers), interquartile range (box), median (horizontal line) and all individual values. Pt, patient.
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In 9 of 12 patients, frequencies eventually dropped below 3%, and 7 received a second infusion ( Fig. 2g and Extended Data Fig. 7b ). Patients 20 and 24 declined second infusions. Infusions administered after patients had received the maximum targeted cell dose were followed by low-dose, subcutaneous IL-2, but no direct benefit was observed ( Supplementary Fig. 4 ). Unlike our previous observations 14 , T TCR-C4 cell numbers in these patients with no detectable AML were not higher in bone marrow than in blood, suggesting absence of persisting AML cells ( Supplementary Fig. 5 ).
Infused TCR C4 -transduced clonotypes (median 41, range 17-245) were identified by high-throughput TCRβ chain sequencing (HTTCS) for their endogenous EBV-specific TCR (Supplementary Table 1 . In 8 patients who maintained responses in vivo for >84 d after 1 infusion, a median of 5.5 (range 1-9) infused clonotypes ultimately composed >80% of transferred cells detected at the last analysis time-point (Fig. 2h) , suggesting that most persistent responses were mediated by oligoclonal T cells. The persisting clonotypes were also the most frequent in the T TCR-C4 infusion products, suggesting preferential expansion during in vitro stimulation (Fig. 2h, left column) .
The function and phenotype of persisting T TCR-C4 was examined. Compared with cell products at infusion, T TCR-C4 tet + cells Letters Nature MediciNe persisting in vivo expressed significantly higher levels of CD28, CD27 and CD12, CD62L and CCR7 (Fig. 3a , top and middle panels) [21] [22] [23] [24] . Persisting T TCR-C4 also maintained expression of PD1, but not TIM3 or LAG3 (Fig. 3a , lower panels) 25 . T TCR-C4 demonstrated not only maintenance of in vivo function, but also greater responsiveness to the WT1 versus EBV peptide, both pre-infusion and at 30 and 100 d post-infusion (Fig. 3b) , probably reflecting the observed downregulation of the endogenous EBV-specific TCR (Fig. 1d) . As a fraction of the T TCR-C4 was still capable of signaling through the endogenous TCR, the transferred T cells might have been expanded in vivo by exposure(s) to EBV. Therefore, we assessed whether EBV was detectable in patient sera after transfer (Fig. 3c, top panel) . Surprisingly, low-level EBV viremia was detectable 1 d after the initial T cell infusion (median 160 IU, range 0.1-420 UI), with no evidence of EBV reactivation at later time-points; non-specific induction of cytomegalovirus (CMV) viremia was not detected (median 0.01, range 0.01-72) (Fig. 3c , lower panel, and Supplementary Table 2 ). Thus, the transferred T cells may have targeted EBV reservoirs immediately after infusion, which may have also served as a vaccine stimulus to T TCR-C4 (ref.
32
). The origin of persisting clonotypes in vivo was evaluated. Using published criteria 33 , infused clonotypes were classified largely (median 96.7%) within the CD45RA−CCR7− effector memory (T EM ) subset (Extended Data Fig. 8a,b ). However, persisting T TCR-C4 included T EM , terminally differentiated (T TD ) and T CM subsets (median 83%, 5% and 4.8%, respectively, at 100 d). In 4 patients analyzed >84 d post-transfer, nearly all clonotypes (98.8%) of persisting WT1/tet + T TCR-C4 in T CM fractions were also found in T EM (Extended Data Fig. 8c,d ). These results are similar to the subset evolution we observed for melanoma-and human immunodeficiency virus (HIV)-specific T cells after adoptive transfer in patients 34, 35 , and as seen in a primate model 8 , suggesting that T CM acquire effector differentiation markers during in vitro expansion while retaining imprinted T CM characteristics that are re-expressed in a subpopulation after transfer.
To assess the molecular qualities of long-term persisting T TCR-C4 , we used single-cell RNA sequencing (scRNAseq) to probe the transcriptional profile of transferred T TCR-C4 subsets in vivo and determine whether in vitro expansion and expression of TCR C4 altered the gene expression profile of the host cells. Unsupervised clustering analyses 36 performed on PBMCs from patients 10 (11,232 cells) and 18 (7,140 cells) at 320 and 253 d after infusion, respectively, revealed 9 distinct cell clusters visualized in a 2-dimensional projection of t-distributed stochastic neighbor embedding (tSNE) 37 (Fig.  3d) . Expression of transcripts for cluster-specific encoding genes showed common PBMC populations (Extended Data Fig. 9 ). T TCR-C4 were readily distinguished among CD8 + T cells by the codon-optimized TCR C4 sequence (Fig. 3e) . T TCR-C4 grouped with endogenous CD8 + T cells, revealing similar transcription profiles. Compared with endogenous CD8 + T cells, T TCR-C4 expressed higher transcript levels of only six genes (Extended Data Fig. 10 ). This suggests that transferred T TCR-C4 were not permanently significantly altered by the earlier in vitro manipulation and re-infusion.
Despite advances in cell therapy and synthetic biology, no broadly effective T cell therapy yet exists for AML 38 . We and others previously showed that WT1 is a relevant target in AML 9,12,14 and we isolated the high-affinity, WT1-specific TCR C4 . When introduced into donor EBV-specific T CM -enriched T cells 7 , resulting T TCR-C4 persisted post-transfer and prevented relapse in 12 poor-risk patients treated post-HCT.
T TCR-C4 infusions were well-tolerated, with no toxicity to tissues expressing physiologic levels of WT1 and no apparent promotion of GVHD, although we could not formally exclude participation of contaminating cells or cells expressing the WT1-specific TCR in patients who experienced post-infusion GVHD. We also observed no HCT-related deaths in the 12 T TCR-C4 -treated patients. There is no purported role for T TCR-C4 to reduce HCT-related non-relapse mortality and the lack of such events in our TCR C4 -treated group could be due to the limited patient numbers.
Paradoxically, the inability to detect leukemia post-HCT in these patients who have all had sustained remissions made formal assessment of direct T TCR-C4 anti-tumor activity challenging. Therefore, to provide a clinical context and to approximate how many T TCR-C4 -treated patients would have been expected to relapse, we compared the treatment group with a concurrently transplanted similar group of patients using clinically accepted pre-HCT risk stratification indices [1] [2] [3] 39 . The incidence of post-HCT chronic GVHD was also similar in both groups, revealing that the treated group did not have a GVL advantage over the comparative group 30 . Based on all of these factors, the treated patients, none of whom have relapsed, would be expected to have a decreased RFS, comparable to patients in the comparative group, who had an RFS of 54% at 3 yr.
T TCR-C4 introduced into EBV-specific donor CD8 T cells provided surprisingly high levels of engraftment and long-term persistence. A few 'fit' clonotypes that preferentially expanded ex vivo ultimately represented the majority of cells persisting in vivo 31 . Although infusion products were composed primarily of T EM , a limited population of T EBV-TCR-C4 clonotypes progressively accumulated as T CM in vivo. This is reminiscent of results in macaque models 8 , suggesting that expanded EBV-specific T TCR-C4 include cells that can establish long-term T CM -like cells post-transfer. The high-level persistence was obtained without preconditioning the patients, affirming that lympho-and/or myelo-ablation is not an absolute requirement to establish long-term T cell persistence 14 . Thus, the inherent quality of individual infused cells appears to contribute to therapeutic efficacy.
The transfer of T EBV-TCR-C4 might also have distinct therapeutic advantages over other T CM populations, as these cells can potentially also respond to known viral antigens 40 . Low-level EBV reactivation + T TCR-C4 within the infusion products (n = 12), and after ~30 d (n = 9) and ~100 d (n = 8) in vivo in patients who had >1% detectable T TCR-C4 tet + cells, which produced IFN-γ (top graph), TNF-α (middle graph) and/or IL-2 (bottom graph) in response to 1 μM WT1 peptide. Box and whisker plots include range (whiskers), interquartile range (box), median (horizontal line) and all individual values. Two-sided paired t-tests were used for statistical analysis. NS, not significant. c, EBV (top graph) and CMV (bottom graph) viremia (IU ml −1 , y axis) measured after each infusion for all patients (EBV) and in the subset in which the patient and/or donor were CMV + , respectively (Supplementary Table 2 ). The number of values (n) obtained after infusions is indicated above the time-point. Median and interquartile range are shown. Two-sided paired t-tests were used for statistical analysis. d, tSNE visualization of clustering of PBMCs for selected patient 10 (top) and patient 18 (bottom) after 320 d and 253 d in vivo, respectively. Cells clustered into populations, as indicated. Representative marker genes shown in Extended Data Fig. 9 . e, Location in clusters of CD8 + lymphocytes carrying the TCR C4 transgene (blue) for each respective patient. Consistent with flow cytometry data (Fig. 3a) , most T TCR-C4 clustered with endogenous CCR7 -populations and a small subpopulation clustered with CCR7 + populations (for patients 10 and 18, respectively, 1.44% and 2.8% in the scRNAseq CCR7 + cluster, compared with 2.86% and 3.2% by flow cytometry). Note: T cells and monocytes sometimes form doublets attached to the same gel-bead, which can result in some T TCR-C4 clustering with monocytes. DCs, dendritic cells; NK cells, natural killer cells. . This can be addressed in future studies by comparing outcomes after transfer of EBV-specific versus non-EBV-specific T CM populations.
Our results are very encouraging and warrant further study in larger randomized trials, to formally determine whether T TCR-C4 can reproducibly reduce the risk of leukemic relapse in high-risk AML patients after chemotherapy or HCT. 3 , AML beyond first remission, primary refractory AML, therapy-related AML, AML arising in patients with antecedent hematologic disorders and/or AML with evidence of minimal residual disease (MRD)/overt disease at time of HCT [1] [2] [3] . Additionally, exclusion criteria included: active central nervous system disease, HIV seropositivity, grade ≥ 3 GVHD and no available EBV-seropositive matched donor. Patients with no detectable disease post-HCT received treatment on the prophylactic arm discussed here, and patients with evidence of disease post-HCT received T TCR-C4 on the treatment arm (not described here) (Extended Data Fig. 1 ). The sample size for this study was not based on formal power calculations, but on feasibility and the potential to provide descriptive information, determine whether further study was warranted and reveal whether the toxicity was acceptable.
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Treatment plan. Patients were eligible to receive a first infusion of T TCR-C4 only after demonstrating hematologic engraftment, absence of grade ≥ 3 GVHD and NED by morphology, flow cytometry or molecular analyses on marrow assessments performed at day ~28 and within 3 weeks before the first infusion. Comparative group selection and characteristics. Patients who underwent HCT for AML during the study enrollment period and were not enrolled on the study protocol (reasons included HLA-A2 negative, participation in transplant protocols with relapse as endpoint 42 and declined participation), but who met criteria for treatment on the prophylactic arm (other than HLA-A2 expression) were consented on an observation protocol (FHCRC no. 999) and included in the comparative group. Patients in the comparative group were further slected to have absence of grade 3 GVHD before day 80, NED at their first (~28 d) and, when available, second (~80 d) post-HCT marrows. This corresponded to the time patients enrolled on the prophylactic arm generally became eligible to receive infusions (Extended Data Fig. 3) . We estimated the post-HCT relapse risk for both groups based on pre-HCT AML and clinical characteristics using three different stratification algorithms currently used clinically to classify patients and predict outcomes: the European LeukemiaNet risk-stratification based on AML cytogenetic and molecular factors Of the treated and comparative group patients, 33.3% and 15.7%, respectively, fell in the high/very high classification, and 66.6% and 85.2%, respectively, fell in the low/intermediate classification, revealing that a larger proportion of treated patients had a higher risk of relapse when using the post-HCT Disease Risk Index. MRD entering transplant is associated with an RFS of 12% at 3 yr 1 . Again, a higher proportion of treated patients (25%) had MRD entering HCT compared with the comparative group (14%), revealing that treated patients were proportionally more at risk for relapse than comparative group patients. A reduced-intensity pre-HCT conditioning regimen is also associated with a lower RFS, which is estimated at 60% at 2 yr 39 . For this factor, the groups were similar, as both had 25% of patients who received a reduced-intensity pre-HCT conditioning. Finally, the incidence of chronic GVHD, which is associated with a potentially beneficial GVL effect 30 , was similar in both groups (55% in T TCR-C4 and 61% in comparative group patients respectively), revealing that the treated group did not have a GVL advantage over the comparative group. 27 were routinely performed on bone marrow aspirates that were obtained from all patients. Any level of residual disease was considered to indicate positivity for MRD.
Isolation of TCR C4 and lentiviral vector construction.
More than 1,000 T cell clones from >50 HLA-A2 + healthy donors (of which 25 had participated in our previous study) 14 were screened to identify high-avidity WT1-specific clones. T cell lines recognizing WT1 126-134 peptide (RMFPNAPYL) were generated for each donor, cloned by limiting dilution, and screened for high functional avidity for an HLA-A2 + TAP-deficient B-lymphoblastoid cell line (T2 B-LCL) pulsed with the WT1 126-134 peptide, as previously described 14 . The clone selected as TCR donor, C4 (TCR C4 ), demonstrated the lowest dissociation constant (K d ) value for tetramer binding. TCR C4 Vα1.3 and Vβ17 TCR chains were isolated using rapid amplification of complementary DNA ends PCR and sequenced. Based on the wild-type sequences, the final construct was synthesized by GeneArt in a codon-optimized format to promote high-level protein expression in human cells 44 . The final construct was engineered to encode a single open reading frame consisting of the TCRβ and TCRα chains, separated by a 2A element from the porcine teschovirus (P2A) to ensure coordinated gene expression 20, 45 . The construct was designed to incorporate complementary cysteine residues at positions 48 (Thr to Cys) and 57 (Ser to Cys) of the constant domains of the TCR C4 α and β genes, respectively, to enhance appropriate inter-chain pairing and discourage mispairing of TCR C4 chains with endogenous TCR chains 46 . The TCR C4 gene construct was then inserted into the pRRLSIN.cPPT.MSCV/GFP.wPRE vector obtained from the laboratory of Richard Morgan after excising the green fluorescent protein (GFP) gene 20 .
Generation of T TCR-C4 .
All ex vivo manipulations involving processing of products destined for infusion were performed in the cGMP Cell Processing Facility of FHCRC. The substrate CD8 + T cells for generating the TCR C4 -transduced T cells (T TCR-C4 ) were obtained from an aliquot the G-CSF stimulated PBMC donation (mobilized leukapheresis) of allogeneic stem cell donors of patients enrolled in protocol FHCRC no. 2498. Cells were stimulated with the HLA-A2-restricted EBV (EBV 280-288 BMLF1 (GLCTLVAML)) peptide. On day +1 and day +2 of the stimulation, the responding cells were transduced using the pRRLSIN.cPPT. MSCV/TCR C4 βP2ATCR C4 α.wPRE lentiviral vector at a target multiplicityof-infection of ≤3. Protamine sulfate (10 µg ml −1 ), IL-2 (50 IU ml −1 ), IL-21 (30 ng ml −1 ), IL-7 (5 ng ml −1 ) and IL-15 (1 ng ml −1 ) were added, and the cells were centrifuged at 2,500 r.p.m. for 90 min at 30 °C, and then incubated overnight at 37 °C. On day +12 (±2 d) of the stimulation cycle, CD8 + T cells specific for both WT1 and EBV were sorted by labeling with tetramers that bound selectively to the WT1-specific TCR (allophycocyanin, APC) or the EBV-specific TCR (phycoerythrin, PE) (FHCRC in-house production), using a clinical grade FACS machine in the cGMP-grade Cell Processing Facility. Sorted double-positive cells (to meet specifications for further processing, the purity of sorted doublepositive cells had to be >95%) were then stimulated once or twice using the Rapid Expansion Protocol 47 . CTL products were freshly infused in 17 of 21 infusions. Alternatively, the cells were thawed and washed before infusion, for a total production time of 4-6 weeks. Quality control of the infused products included assessment of inserted lentiviral vector copy number per cell (≤5 copies per cell), envelope of the vesicular stomatitis virus -G protein DNA by quantitative PCR as a surrogate marker for the detection of replication-competent lentivurus (<10 copies per 50 ng DNA), Vβ17 expression (≥30% of live cells) and binding to the WT1 126-134 HLA-A2-restricted tetramer (≥30% of live cells).
Comparative avidity of T TCR-C4 .
Jurkat-Nur77 T cells (Jurkat cells transduced with CD8αβ and mTomato fluorophor knocked in the Nur77 locus-gifted from Juno Therapeutics) were lentivirally transduced with TCR C4 , or with TCRs isolated from infused WT1-specific clonal cell products from our previous study (patients 1, 15, 20 and 27) 14 , and sorted to yield a uniformly tetramer positive (tet + ) cell population. Sorted cells were expanded and then mixed 1:1 with T2 B-LCL pulsed with titrating doses of the HLA-A2-restricted WT1 126-134 peptide. After 48 h of incubation at 37˚C, cells were analyzed by flow cytometry to determine the percentage of (Nur77) mTomato + Jurkats for each sample. These data were fit to dose-response curves by nonlinear regression using GraphPad Prism 7 (4 parameter-variable slope, with the bottom and top of the curve constrained to 0 and 100, respectively), to determine half-maximal effective peptide concentration for stimulation. AML cytotoxicity assay. T TCR-C4 were cultured with primary AML cells at the indicated effector-to-target ratios in triplicate for 18 h as previously described 48 . Briefly, after the culture period, surviving AML cells were identified by staining for CD45, CD34, CD38, CD117, CD15, CD90, CD96, CD123 and HLA-DR (BioLegend) and quantified with Flow Count beads (Molecular Probes). Percentage killing was calculated by the formula: (absolute number of AML targets in coculture/absolute number of AML targets in target-only control well) × 100.
Immunohistochemistry. WT1 immunohistochemistry was performed by a
College of American Pathologists Clinical Laboratory Improvement Amendmentscertified laboratory with the standard clinical protocol. Paraffin-embedded core bone marrow biopsies or particle preparations were sectioned (4 µM) and antigen Letters Nature MediciNe retrieval performed by heat treatment in 10 mM sodium citrate buffer (pH 6) before staining with DAKO mouse anti-WT1 monoclonal antibody clone 6F-H2, at 1:800 dilution (Supplementary Fig. 3 ).
T cell tracking by WT1 peptide/HLA (pHLA) tetramers. WT1 pHLA-specific tetramers (produced by the FHCRC Immune Monitoring Core Facility) were used to detect T TCR-C4 in PBMCs collected after infusions, with a staining sensitivity of 0.01% of total CD8 + T cells, as previously described 35 .
Clonotype identification and tracking by HTTCS.
To identify clonotypes composing infused T TCR-C4 , HTTCS analysis was performed on WT1/HLA-A2 pHLA tet + cells from the infusion products to obtain >99% purity. As the TCR C4 sequence was codon-optimized, HTTCS could not identify the introduced WT1-specific TCR. Instead, HTTCS identified clonotypes based on the endogenous EBV-specific TCR sequence. To track the identified clonotypes, HTTCS was performed on whole PBMCs obtained after transfer, as described 31 . Briefly, DNA was extracted from T cell products and sorted PBMCs using Qiagen Maxi DNA Isolation Kits (QIAGEN). TCRβ CDR3 regions were amplified and sequenced from 750 ng extracted DNA by Adaptive Biotechnologies using the ImmunoSEQ assay as previously described using 'deep' resolution 49 . Raw sequence data were filtered using the Adaptive Bioinformatic website based on the TCRβ V, D and J gene definitions provided by the International ImMunoGeneTics collaboration 50 , using the ImMunoGeneTics database (www.imgt.org). Productive nucleotide sequences were used for all tracking experiments. The limit of detection of HTTCS was set at 0.001% of all TCR reads, below which frequency could not be reliably determined 51 . Only clonotypes present in the infusion products were tracked in PBMCs obtained after infusions. However, clonotypes in the infusion product that were not detected in vivo after infusions and which did not undergo expansion throughout the ex vivo culture process, signifying bystander clonotypes, were eliminated from further analysis 31 . The frequency of each clonotype detected by HTTCS is based on all TCR Vβ reads, which include CD4
+ and CD8 + T cells.
Phenotypic evolution of clonotype subsets.
To determine whether the individual infused clonotypes with T EM characteristics had evolved in vivo to include alternative subsets (T CM or T TD ), PBMCs obtained at ~100 d from patients 10, 11, 12 and 24, who were selected based on T TCR-C4 persistence and sample availability, were flow-sorted for T EM , T CM or T TD tet + cells, and the clonotypes comprising each subset were determined. Supplementary Fig. 2 . Of note, phenotypic studies were performed on bulk T TCR-C4 tetramer + cells, but, since TCR clonotypes were determined by HTTCS following extraction of DNA from killed cells, it was not possible to determine the phenotypic characteristics of clonotype-specific T TCR-C4 .
Dual tetramer and intracellular cytokine staining. Cryopreserved PBMCs were thawed and rested overnight in RPMI medium, supplemented with 10% fetal bovine serum (R10). Intracellular cytokine staining and stimulations were performed using a 15-color staining panel, as previously described 52 , with the following modifications: tetramers specific for HLA-A2/WT 126-134 (APC) and HLA-A2/EBV 280-288 (PE) were added at 1:1,000 and 1:400, respectively, in 50 μl R10 and incubated for 30 min at room temperature before either the addition of the stimulation cocktail containing either the WT1 126-134 , EBV 280-288 peptide in R10 at a final peptide concentration of 1 μg ml −1 or the addition of R10 with an equivalent amount of dimethylsulfoxide used to preserve the peptides (negative control). The staining panel was modified to accommodate the addition of the PE and APC tetramers, by excluding IL-21, CD56 and CXCR5; changing IL-2 to PE-dazzle 594 (clone MQ1-17H12, Biolegend); and adding granzyme B on Alexa 700 (clone GB11, BD Biosciences). Cells were analyzed on an LSRII instrument (Becton Dickinson), using FACS-Diva software v.8.0.1. The resulting flow cytometry data were analyzed using FlowJo v.9.9.4 (Treestar). Percentage cytokine expression (percentage of tetramer + cells that are both cytokine + and tetramer + in the dimethylsulfoxideonly sample (negative control)) was calculated for each sample. Percentage of tetramer + cytokine + cells in the presence of dimethylsulfoxide without peptide varied among samples from 0 to 2.27%, with a median of 0.745%. A representative example of the initial gating algorithm is shown in Supplementary Fig. 1 .
Serum EBV and CMV quantification. EBV PCR: primers specific for the EBER gene were developed at the FHCRC 53 . The limit of quantitative detection (the minimum virus level that gives a positive result in 95% of replicates) is 250 IU ml −1 (2.40 log IU ml
). Quantitative results less than 250 IU ml −1 are described as very low positive. CMV PCR: primers specific for the UL123 and gB genes were developed at the FHCRC 54 . The limit of quantitative detection (the minimum virus level that gives a positive result in 95% of replicates) is 20 IU ml ). Quantitative results less than 20 IU ml −1 are described as very low positive. Results for 21 infusions in total, 15 of which could be assessed in patients who had sufficient post-infusion material available for analysis, are shown in Fig. 3c. scRNAseq. Cell were thawed, washed and labeled in a single fashion using the 10X Genomics 3' Chromium v.2.0 platform as per manufacturer's instructions. Library preparation was performed as per manufacturer's protocol with no modifications. Library quality was confirmed by Agilent 2200 TapeStation high sensitivity (evaluates library size), qubit (evaluates double-stranded DNA quantity) and KAPA quantitative PCR analysis v.4.14 (KAPA Biosystems, evaluates quantity of amplifiable transcript). Samples were mixed in equimolar fashion and sequenced on an Illumina HiSeq 2500 rapid run mode according to standard 10X Genomics protocol.
Computational analysis for scRNAseq transcriptome alignment, barcode assignment and unique molecular identifier (UMI) counting. The Cell Ranger Single-Cell Software Suite (v.2.0.0) was used to perform sample demultiplexing, barcode processing and single-cell 3' gene counting (http://10xgenomics.com/). First, raw base BCL files were demultiplexed using the Cell Ranger mkfastq pipeline into sample-specific FASTQ files. Second, these FASTQ files were individually processed using the Cell Ranger count pipeline. Reads, which contain cDNA inserts, were aligned to the hg38 human reference genome (Ensembl) and the known transgene codon-optimized sequence using STAR 55 . Aligned reads were then filtered for valid cell barcodes and UMIs. Cell barcodes with 1-Hamming-distance from a list of known barcodes were examined. UMIs with sequencing quality score >10% and not homopolymers were retained as valid UMIs. A UMI with 1-Hammingdistance from another UMI with more reads, for a same cell and a same gene, was corrected to this UMI with more reads. The default estimated numbers of cells used were 7,500 and 10,000 cells for patients 10 and 18, respectively.
Data normalization.
Samples from patients 10 and 18 were aggregated for data normalization. UMI normalization was performed as proposed by Seurat 37 . First, only genes with at least 1 UMI count detected in at least 3 cells were kept (16,639 genes from 18,493 cells). Then, for each cell, a library-size normalization was performed. UMI counts were divided by the total number of UMIs in each cell followed by a multiplication by 10,000. Data were then natural-log transformed before analysis using Seurat and Model-based Analysis of Single Cell Transcriptomics (MAST). Regressing uninteresting sources of variation can improve downstream analyses 56 . We used the specific ScaleData R function implemented by Seurat on the normalized matrix to remove technical effects due to the library size (number of UMIs-highly correlated with the number of genes detected) and the percentage mitochondrial gene content, as proposed by Seurat. As high mitochondrial gene expression might be suggestive of low-quality libraries 57 , the corrected gene-barcode matrix was used as input for downstream analyses (dimension reduction and clustering). In MAST, the normalized gene-cell barcode matrix was used as input and the number of genes detected was taken into account, as proposed 58 . We elected to filter out 121 outlier cells having unique gene counts less than 250, percentage of mitochondrial genes more than 15%, or more than 20,000 UMIs, discarding <1% of cells. The percentage of UMI mapping to mitochondrion-related genes is a common scRNAseq quality metric-high mitochondrial gene expression is suggestive of low-quality libraries 57 .
Statistical methods.
(1) Statistical methods for comparison of treated and comparative group patient outcomes. Cox regression was used to compare risk of overall mortality and relapse, failure for RFS (earliest of relapse or death) and chronic GVHD between patients who received T TCR-C4 and comparative patients who survived without relapse to ~day 28 or ~day 80. Time zero was time of HCT, and the data were considered to be left-truncated, with patients not entering the risk set until day 28 (n = 18) or day 80 (n = 70) for the comparative group patients, or the last NED marrow before T cell infusion for the treated group. Comparative patients with NED both at ~day 28 and day 80 entered the risk set at day 80. To account for different T cell infusion times, a time-dependent covariate assumed a value of zero throughout for comparative group patients and a value of zero for the treated group until the time of T cell infusion, at which point the time-dependent covariate assumed a value of 1 (ref.
59
). For example, the patient who received a first infusion on day 190 was, for analysis purposes, evaluated as being in the comparative group up until day 190. This approach is a means to take into account lead-time (or immortal-time) bias that results from the fact that patients were evaluated for and that patients who received T TCR-C4 did so at varying times (timing between HCT and NED assessment ranged from 28 to 173 d; timing between HCT and T TCR-C4 infusions ranged from 47 to 190 d), and hence they had lived without relapse long enough to receive T TCR-C4 . Since there were no deaths or relapses in the T cell group, P values for comparing groups for the outcomes mortality, relapse and RFS were estimated from the likelihood-ratio test. An effect size could not be calculated as there were no failures in the treated group. For chronic GVHD, the P value from the regression model was estimated from the Wald test. Kaplan-Meier estimates of overall survival and RFS were calculated for the comparative group patients and cumulative incidence estimates were used to summarize the probability of relapse (treating death without relapse as a competing risk) from time of NED assessment. Seurat was used to compute dimension reduction and clustering analyses. First, principal component analyses were performed, using the top 1,736 variable genes (defined by log-mean expression values greater than 0.0125 and dispersion (variance/mean) greater than 0.5). Then, the top ten principal components (PCs) were selected for tSNE visualization for both patients. To determine the number of principal components to use, the Jackstraw procedure, elbow plot and supervised analysis (PCHeatmap) were all explored; reassuringly, all three yielded similar results. One thousand iterations of the tSNE algorithm (Barnes-Hut implementation) using a perplexity value of 30 and the top 10 PCs were performed for both patients. We then classified the cells according to a graph-based clustering method as proposed by Seurat (FindClusters R function-share nearest neighbor modularity optimizationbased clustering algorithm). A total of nine clusters were identified, most of which were well-distributed across both samples (Extended Data Fig. 9 ). For both patients, the annotation of the clusters was performed using the FindAllMarkers R function implemented by Seurat, which finds makers for each of the identity classes. Cluster identity was confirmed by manual review. Cells corresponding to platelets and platelet doublets (2 cells in the same gelemulsion complex) were removed (356 and 316 cells in patients 10 and 18, respectively), leaving a total of 9 clusters. Two populations of CD8 + T cells were present, mostly driven by CCR7 expression (Extended Data Fig. 9 ). Consistent with flow cytometry data ( Fig. 3 and Extended Data Fig. 2 ), the majority of T TCR-C4 did not express CCR7 and thus differential expression analysis was only possible on the CCR7 -clusters (orange and red clusters in Fig. 3e ) due to cell number. Differential expression analysis of transgenic T cells versus nontransgenic T cells was performed using the MAST R/Bioconductor package for analyzing single-cell gene expression data 31 . MAST provides functionality for significance testing of differential expression using a Hurdle model, gene set enrichment and facilities for visualizing patterns in residuals indicative of differential expression. It is a two-part generalized linear model that simultaneously models the rate of expression over the background of various transcripts (logistic regression), and the positive expression mean (Gaussian). These tests are two-sided and adjust for the bimodal nature of scRNAseq data. Differential expression was performed separately with the same approach for each patient, to account for patient-specific differences. The normalized gene-cell barcode matrix was used as input. The model included the cellular detection rate as a covariate to correct for biological and technical nuisance factors that can affect the number of genes detected in a cell (for example, cell size and amplification bias). Genes were declared significantly differentially expressed at a false discovery rate of 5% and a fold-change >1.3.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
All requests for raw and analyzed data and materials will be promptly reviewed by the Fred Hutchinson Cancer Research Center to verify whether the request is subject to any intellectual property confidential obligations. Patient-related data not included in the paper were generated as part of a clinical trial and may be subject to patient confidentiality. Any data and materials that can be shared will be released via a Material Transfer Agreement. PBMC scRNAseq data for patients 10 and 18, as well as the R code to generate the tSNE plots using Seurat software packages, are available at the National Center for Biotechnology Information Gene Expression Omnibus, accession number GSE128933. Fig. 1 | Flow diagram of patients enrolled on the clinical study. Follow-up of the 64 patients screened for participation in the study. Patients could either enter the study by being screened/enrolled pre-HCT (49 patients) or after post-HCT relapse (15 patients). Patients with no detectable disease at day ~28 post-HCT were eligible to receive treatment on the prophylactic arm described here, and patients with evidence of relapse post-HCT alternatively received therapy on the treatment arm (not described here). Between 29 April 2013 and 19 October 2016, 29 patient/donor pairs were enrolled pre-HCT. Of these, TCR C4 -transduced cells were initiated for 23 patients, and 12 patients who had not relapsed before day 28 received TCR C4 -transduced cells on the prophylactic arm. One additional patient was considered not evaluable for response outcomes as this patient received <12% the intended dose and was unable to receive further infusions due an inability to generate additional T cells from the donor. Black asterisks indicate timing of T TCR-C4 infusion and blue asterisks indicate that the infusion was followed by low-dose subcutaneous IL-2. c, Graphs to the left, frequency of the first 25 most frequent clonotypes (shaded in color) and remainder of the clonotypes (shaded in gray) expanded and detected at any time-point after infusions (Supplementary Table 1 ) present in infusion products in selected patients (n = 11). The proportions of the sum of clonotype frequencies present in the infusion product but not detected after infusion are indicated in white (see Supplementary Table 1 The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Sample size
The sample size for TTCR-C4 treated patients (n=12) was not based on formal power calculations. Rather, on feasibility, the potential to provide descriptive information to determine whether further study was warranted and to reveal if the toxicity was acceptable. The sample size for the comparative group (n=88) was based on all patients who would have been eligible for TTCR-C4 infusions at the same institution during the same time study patients were being enrolled but did not receive them. Reasons for not receiving TTCR-C4 included absence of HLA A*0201 expression, participation in transplant protocols with relapse as endpoint, and patients who declined participation. Inclusion was further limited to pts with absence of grade 3 GVHD before day 80, NED at their first (~28 days) and when available 2nd (~80 days) post-HCT marrows, corresponding to the time pts enrolled on the Prophylactic Arm generally became eligible to receive infusions.
Data exclusions Patients received TTCR-C4 based on pre-established inclusion and exclusion criteria. Eligibility for enrolment (after which a T cell product was started) included HLA A*0201-expression, patients undergoing allogeneic transplant from a matched donor, high-risk AML. Exclusion for enrolment included CNS disease refractory to intrathecal chemotherapy, HIV seropositivity, a medical or psychological condition that would preclude them from receiving treatment, pregnancy or breastfeeding. Exclusion for treatment on the Prophylactic Arm (described here) further included patients with overt relapse or MRD prior to a first TTCR-C4 infusion, occurrence of Grade ≥3 GVHD, anti-thymocyte globulin or other T cell suppressive treatment within 1 month of a first TTCR-C4 infusion, prednisone >0.5mg/kg/day, graft rejection or failure, Karnofsky performance status score ≤ 40%, unable to generate adequate numbers of TTCR-C4. For single cell RNA seqencing, we determined a priori to only analyze nucleated cells from the peripheral blood. Cells corresponding to platelets, and platelet doublets (two cells in the same gel-emulsion complex) were removed (356 and 316 cells in patients 10 and 18 respectively), leaving a total of 9 clusters. We then elected to filter out 121 outlier cells having unique gene counts less than 250, percentage of mitochondrial genes more than 15% or more than 20,000 UMIs, discarding <1% of cells. The percentage of UMI mapping to mitochondrion-related genes is a common scRNAseq quality metric -high mitochondrial gene expression is suggestive of low-quality libraries. No other exclusions were performed.
Replication
For Figure 1B : The median and standard error of 3 triplicates for each value are shown. For Figures 1D, E , F, G; Figure 3A and Figures 4A and B: all attempts at reproduction of persistence/phenotype and cytokine expression were successful. For Figure 5 : the reproducibility of findings in panels A and B (2 panels each), are shown in Figure S12 . For Figure S3 : three sections were identified for each image and were similar.
Randomization No randomization was performed for the treated patients as the clinical trial was designed as Phase I/II study.
Blinding
All clinical data from treated and comparative group patients (e.g. lymphocyte counts, platelets, hematocrit, marrow immunohistochemistry, clinical flow cytomtry, clinical cytogenetics) were taken from clinical lab reports and therefore blinded. For all other laboratory studies care was taken to perform all manipulations on the same day and under the same experimental conditions. Patient group allocation could not be blinded as the screening and logistics necessary to infuse patients with TTCR-C4 required coordination between multiple groups.
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express HLA A*0201 by high-resolution typing, have a 10/10 matched related or unrelated donor and be disease-free at the time of hematopoietic recovery ~28 days after transplant.
Comparative group patients (n=88) were selected based on their meeting study entry criteria during the study enrollment period, except for the HLA A*0201 expression requirement. These patients were not enrolled on the study protocol for reasons including HLA-A2 negative, participation in transplant protocols with relapse as endpoint, and declined participation. Inclusion was further limited to patients with absence of grade 3 grafte versus host before day 80, no evaluable dosease at their first (~28 days) and when available 2nd (~80 days) post-transplant marrows, corresponding to the time treated patients became eligible to receive infusions.
For treated and comparative group patients respectively, their median age was 59 and 55 years old, 58.3% and 51.1% were male, 50% and 50% had adverse risk AML based on their AML cytogenetic profile, 8.3% and 2.3% had extramedullary disease, 41,6% and 20.5% had persistently detectable AML after a first induction cycle, 33.3% and 28.4% received treatment after having required more than one induction to achieve remission, 16.7% and 22.7% had secondary or treatment-related AML and 33.3% and 19.3% had detectable disease immediately before transplant. The detailed characteristics of treated patients are described in Table 1 . Characteristics of treated and comparative group patients are provided in Extended Data 1.
Recruitment
All HLA A*0201+ participants were identified through the Clinical Coordinator's Office who tracks every patient who is referred to Fred Hutch for allogeneic transplantation. The Attending Physician on the Transplant Service was notified and the study was presented to potential participants during their Arrival Conference on the Transplant Service by the Attending Physician. Both the Clinical Coordinators and Attending Physicians (who rotate on a monthly basis) were not part of the research team. If the patient was interested in participating, they then signed the Screening informed consent to formally determine their eligibility. If they met screening criteria and remained interested in participating, they signed the Treatment informed consent. Patients then went on to undergo their allogeneic transplant. A portion of the donor GCSF-mobilized donation used to generate the cells which were infused as soon as participants could receive them. As this was not a randomized study and this study relied heavily on patients wanting to participate (for example, some patients had to stay longer on the bone marrow transplant service instead of being able to go home after their transplant to receive the cells), we cannot exclude a self-selection bias that could have impacted the results.
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Methodology Sample preparation
Peripheral Blood Mononuclear Cells (PBMC) and bone marrow aspirates: White blood cells from the described patients were collected with standard phlebotomy/marrow aspirates, isolated with standard Ficoll gradient, and viably cryopreserved. Infusion product: Please see methods section for full description of preparation of therapeutic product. For all flow cytometry, cryopreserved PBMCs or marrow lymphocytes were thawed and rested overnight in RPMI supplemented with 10% fetal bovine serum (FBS) (R10) before staining/assay performance. Cell population abundance At least 1 x 10E6 events gated on the lymphocyte population were acquired for each sample.
Instrument
Gating strategy
Gating strategy for intracellular assays: Initial gating was on singlet (FSC-A vs. FSC-H), followed by exclusion of dead cells and CD14-expressing antigen presenting cells (FSC-A vs. AViD/CD14 BV510), followed by lymphocyte identification (FSC-A vs. SSC-A), followed by CD3 identification (CD3 BV570 vs CD8 BV711), followed by CD8 gating (CD4 BUV395 vs CD8 BV711). A representative example is shown in the supplement. Gating strategy for surface stains: Initial gating was on lymphocytes (SSC-A vs. FSC-A), followed by singlet exclusion (FSC-H vs FSC-A), followed by exclusion of dead cells and CD19/16-expressing cells (AmCyan Live/ dead vs CD19/16 PE-Cy5), followed by CD8 identification (CD4 APC-Cy7 vs CD8 BV605), followed by WT1+ tetramer cells identifying TTCR-C4 (WT1 tet. APC cs CD8 BV605). A representative example is shown in the supplement.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
